Clinical and Genetic Determinants of Contralateral Breast Cancer in Newly Diagnosed Breast Cancer Patients

Join Authentix and David Howard, former Director of Johnson & Johnson Global Brand Protection, to discuss the counterfeit challenges and how to address them through strategic planning and implementation.

Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, is a transformative document that will shape global regulatory submissions and practices.

The COVID crisis has revealed the importance of rapid and optimized equipment design and scale up for drug and vaccine manufacturing processing as well as the necessity to maintain an optimal productivity level throughout the equipment lifecycle.

After the US Food and Drug Administration (FDA)’s stated that “the clinical trial system is broken,” regulatory agencies began working to formally figure out how real-world evidence will be used in new drug submissions and for new uses of existing drugs. The business potential is huge: organizations can reduce the time and cost of bringing new drugs to market by relying on existing real-world data and new sources of unstructured data, e.g., EHRs and social media. Most importantly, this real-world data can get patient-saving drugs to market more quickly with fewer post-release adverse events.